A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

被引：5

作者：

Mulligan, Stephen P.

Gill, Devinder S. ^{[1
]}

Turner, Paul ^{[2
]}

Renwick, William E. P. ^{[3
]}

Harrup, Rosemary ^{[4
]}

Latimer, Maya ^{[5
]}

Mackinlay, Naomi

Berkahn, Leanne ^{[6
]}

Simpson, David ^{[7
]}

Campbell, Philip ^{[8
]}

Tiley, Campbell ^{[9
]}

Cull, Gavin ^{[10
]}

Collins, Marnie ^{[11
]}

Cortissos, Paul ^{[11
]}

Sulda, Melanie ^{[12
]}

Best, Giles ^{[13
]}

Kuss, Bryone J. ^{[12
,14
]}

机构：

[1] Princess Alexandra Hosp, Div Canc Serv, Brisbane, Qld 4102, Australia

[2] Austin Hosp, Melbourne, Vic 3084, Australia

[3] Royal Melbourne Hosp, Parkville, Vic 3050, Australia

[4] Royal Hobart Hosp, Hobart, Tas, Australia

[5] Canberra Hosp, Canberra, ACT, Australia

[6] Auckland City Hosp, Auckland, New Zealand

[7] N Shore Hosp, Auckland, New Zealand

[8] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia

[9] Gosford Hosp, Dept Haematol, Gosford, Australia

[10] Sir Charles Gairdner Hosp, Perth, WA, Australia

[11] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia

[12] Flinders Med Ctr, Adelaide, SA, Australia

[13] Royal N Shore Hosp, Kolling Inst, Sydney, NSW, Australia

[14] Flinders Univ S Australia, Dept Haematol & Genet Pathol, Adelaide, SA 5001, Australia

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.436.436

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

436

引用

页数：3

共 8 条

[1] The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
Mulligan, Stephen P.
Gill, Devinder S.
Renwick, William E. P.
Sulda, Melanie L.
Best, O. Giles
Kuss, Bryone J.
Seymour, John F.
BLOOD, 2010, 116 (21) : 308 - 308
[2] A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity
Mulligan, Stephen P.
Gill, Devinder
Turner, Paul
Renwick, William E. P.
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David
Campbell, Philip
Forsyth, Cecily J.
Cull, Gavin
Harrup, Rosemary
Sulda, Melanie
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone J.
BLOOD, 2014, 124 (21)
[3] Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial
Sandhu, Suneet
Gill, Devinder
Turner, Paul David
Renwick, William E. P.
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David R.
Campbell, Philip
Forsyth, Cecily
Cull, Gavin
Harrup, Rosemary
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone Jean
Mulligan, Stephen
BLOOD, 2015, 126 (23)
[4] Quality of life in fit elderly patients with chronic lymphocytic leukemia (CLL) receiving oral fludarabine-based regimens as first line therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial.
Sandhu, Suneet
Gill, Devinder
Turner, Paul
Renwick, William
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David
Campbell, Phillip
Forsyth, Cecily
Cull, Gavin
Harrup, Rosemary
Sulda, Melanie
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone
Mulligan, Stephen
LEUKEMIA & LYMPHOMA, 2015, 56 : 27 - 29
[5] Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)
Mulligan, Stephen P.
Gill, Devinder
Turner, Paul
Renwick, William E. P.
Latimer, Maya
Mackinlay, Naomi
Berkahn, Leanne
Simpson, David R.
Campbell, Philip
Forsyth, Cecily J.
Cull, Gavin
Harrup, Rosemary
Sulda, Melanie
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone J.
BLOOD, 2014, 124 (21)
[6] TOXICITY AND RESPONSE BY COMORBIDITY AND AGE IN A RANDOMIZED STUDY OF ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE WITH RITUXIMAB FIRST-LINE THERAPY OF FIT ELDERLY WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
Mulligan, S.
Gill, D.
Turner, P.
Renwick, W.
Harrup, R.
Latimer, M.
Cull, G.
Berkahn, L.
Forsyth, C.
Mackinlay, N.
Simpson, D.
Campbell, P.
Tam, C.
Collins, M.
Sulda, M.
Best, G.
Kuss, B.
HAEMATOLOGICA, 2013, 98 : 42 - 42
[7] Dose-reduced FCR first-line therapy in fit elderly CLL patients is safe, tolerable, and highly effective; first report of final statistical analysis from end of study and 12 month follow-up of ALLG CLL5 randomised dose de-escalation study
Mulligan, Stephen
Turner, Paul
Gill, Devinder
Latimer, Maya
Renwick, William
Harrup, Rosemary
Cull, Gavin
Forsyth, Cecily
Mackinlay, Naomi
Berkahn, Leanne
Campbell, Phillip
Simpson, David
Tam, Constantine
Sulda, Melanie
Best, Giles
Bressel, Mathias
Di Iulio, Juliana
Kuss, Bryone
LEUKEMIA & LYMPHOMA, 2015, 56 : 23 - 24
[8] Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
Smolej, Lukas
Brychtova, Yvona
Cmunt, Eduard
Doubek, Michael
Spacek, Martin
Belada, David
Simkovic, Martin
Stejskal, Lukas
Zygulova, Irena
Urbanova, Renata
Brejcha, Martin
Zuchnicka, Jana
Mocikova, Heidi
Kozak, Tomas
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 769 - 778

← 1 →